{"product_id":"tivc-vrio-analysis","title":"Tivic Health Systems, Inc. (TIVC): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eIs Tivic Health Systems, Inc. (TIVC) truly built to last? This VRIO analysis cuts straight to the core, dissecting the Value, Rarity, Inimitability, and Organization of its key resources to reveal the true source of its competitive advantage - or lack thereof. Discover immediately whether Tivic Health Systems, Inc. (TIVC)'s current strengths are fleeting or form an unshakeable foundation for market dominance by diving into the detailed findings below.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eTivic Health Systems, Inc. (TIVC) - VRIO Analysis: 1. Entolimod™ Lead Candidate (ARS Indication)\n\u003c\/h2\u003e\n\u003cp\u003eThe Entolimod™ asset for Acute Radiation Syndrome (ARS) represents a \u003cstrong\u003esustained competitive advantage\u003c\/strong\u003e for Tivic Health Systems, Inc. due to its late-stage regulatory status and clear pathway toward potential government procurement.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eEntolimod™ Lead Candidate (ARS Indication)\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003cp\u003eThe core value proposition here is addressing a critical, low-frequency, high-impact medical countermeasure need. Animal data is compelling, showing a \u003cstrong\u003ethree-fold increase in survival\u003c\/strong\u003e with a single dose 25-hours post-lethal radiation exposure, including GI tract protection. The global ARS market was estimated at \u003cstrong\u003eUSD 5.2 billion\u003c\/strong\u003e in 2024.\u003c\/p\u003e\n\n\u003cp\u003eThe company is aggressively prioritizing this asset, evidenced by securing a BARDA Techwatch meeting on November 18, 2025, to discuss clinical data and manufacturing readiness for potential stockpile consideration. This focus is part of a strategic shift away from the ClearUP business.\u003c\/p\u003e\n\n\u003cp\u003eHere’s the quick math on the asset’s history: Entolimod has been part of over \u003cstrong\u003eforty\u003c\/strong\u003e trials backed by \u003cstrong\u003e$140 million\u003c\/strong\u003e in prior investment.\u003c\/p\u003e\n\n\u003cp\u003eThe VRIO assessment for this specific indication is laid out below:\u003c\/p\u003e\n\n\u003ctable border=\"1\"\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cstrong\u003eVRIO Dimension\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003eAssessment\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003eSupporting Data\/Implication\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cstrong\u003eValue (V)\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eHigh\u003c\/td\u003e\n    \u003ctd\u003eAddresses critical unmet need (ARS); potential for government procurement\/stockpile pathways discussed with BARDA.\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cstrong\u003eRarity (R)\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eHigh\u003c\/td\u003e\n    \u003ctd\u003eHolds both \u003cstrong\u003eFast Track\u003c\/strong\u003e and \u003cstrong\u003eOrphan Drug\u003c\/strong\u003e designations from the FDA for ARS.\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cstrong\u003eImitability (I)\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eDifficult\u003c\/td\u003e\n    \u003ctd\u003eBacked by extensive proprietary development, including \u003cstrong\u003e$140 million\u003c\/strong\u003e in prior investment and numerous clinical trials.\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cstrong\u003eOrganization (O)\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eHigh\u003c\/td\u003e\n    \u003ctd\u003eCompany is fully focused, validating cGMP manufacturing, and has no debt on its balance sheet as of September 30, 2025 (Cash: \u003cstrong\u003e$3.5 million\u003c\/strong\u003e).\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eSustained\u003c\/td\u003e\n    \u003ctd\u003eLate-stage status, regulatory de-risking, and clear federal interest create a strong barrier to entry.\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe rarity is cemented by the specific regulatory badges. It’s defintely not easy to get both Fast Track and Orphan Drug status for a late-stage asset targeting a military countermeasure need.\u003c\/p\u003e\n\n\u003cp\u003eWhat this estimate hides: The current cash position of \u003cstrong\u003e$3.5 million\u003c\/strong\u003e as of September 30, 2025, means execution risk remains high, as further development funding is necessary.\u003c\/p\u003e\n\n\u003cp\u003eKey elements supporting the competitive moat include:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eFDA \u003cstrong\u003eFast Track\u003c\/strong\u003e Designation for ARS.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOrphan Drug\u003c\/strong\u003e Designation for ARS.\u003c\/li\u003e\n  \u003cli\u003eDemonstrated robust survival in animal models.\u003c\/li\u003e\n  \u003cli\u003eActive engagement with BARDA for potential procurement.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eFinance: draft 13-week cash view by Friday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eTivic Health Systems, Inc. (TIVC) - VRIO Analysis: 2. TLR5 Agonist Drug Platform\n\u003c\/h2\u003e\n\u003cp\u003eThe TLR5 Agonist Drug Platform centers on Entolimod™, a Toll-like Receptor 5 (TLR5) agonist that triggers \u003cstrong\u003eNF-kB signaling\u003c\/strong\u003e, activating antiapoptotic and cell protective mechanisms.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue: High;\u003c\/strong\u003e this platform extends beyond ARS, supporting INDs for neutropenia and potential use as an adjunctive therapy in immuno-oncology. The lead candidate, Entolimod™, has been granted \u003cstrong\u003eFast Track Designation\u003c\/strong\u003e and \u003cstrong\u003eOrphan Drug designation\u003c\/strong\u003e by the FDA for Acute Radiation Syndrome (ARS). The global ARS market was valued at \u003cstrong\u003eUSD 5.2 billion in 2024\u003c\/strong\u003e. The company also secured worldwide rights for Neutropenia, a market estimated to exceed \u003cstrong\u003e$20 billion by 2029\u003c\/strong\u003e. The program has benefited from over \u003cstrong\u003e$140 million\u003c\/strong\u003e of prior investment.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity: Medium;\u003c\/strong\u003e while TLR agonists exist, Tivic’s specific data set and expanded license coverage are unique to them. The company holds \u003cstrong\u003etwo Investigational New Drug Applications (INDs)\u003c\/strong\u003e transferred from Statera Biopharma covering ARS and advanced cancers.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability: Medium;\u003c\/strong\u003e competitors can pursue other TLR agonists, but replicating Tivic’s specific clinical progress is time-consuming. This includes the completion of Phase III validation for ARS via the FDA's animal rule pathway and the initial licensing payment of \u003cstrong\u003e$1,200,000 in equity\u003c\/strong\u003e and \u003cstrong\u003e$300,000 cash\u003c\/strong\u003e for the ARS indication.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization: High;\u003c\/strong\u003e the company is actively using this platform to expand its pipeline value beyond the lead indication. The exclusive license for Neutropenia was exercised on \u003cstrong\u003eMarch 28, 2025\u003c\/strong\u003e. Furthermore, the company initiated GMP manufacturing validation with Scorpius BioManufacturing, a program valued at approximately \u003cstrong\u003e$4.1 million\u003c\/strong\u003e, in preparation for a Biologics License Application (BLA) filing for ARS.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage: Temporary to Sustained;\u003c\/strong\u003e success in new indications will solidify this as a sustained advantage.\u003c\/p\u003e\n\n\u003cp\u003eThe TLR5 Agonist Platform Indications and Development Status:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eIndication\u003c\/th\u003e\n\u003cth\u003eStatus\/Designation\u003c\/th\u003e\n\u003cth\u003eMarket\/Investment Data\u003c\/th\u003e\n\u003cth\u003eDerivative\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcute Radiation Syndrome (ARS)\u003c\/td\u003e\n\u003ctd\u003ePhase III Validation Completed; \u003cstrong\u003eFast Track\u003c\/strong\u003e \u0026amp; \u003cstrong\u003eOrphan Drug\u003c\/strong\u003e Designation\u003c\/td\u003e\n\u003ctd\u003eGlobal Market: \u003cstrong\u003e$5.2 billion\u003c\/strong\u003e (2024 est.)\u003c\/td\u003e\n\u003ctd\u003eEntolimod™\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNeutropenia\u003c\/td\u003e\n\u003ctd\u003eWorldwide License Exercised (\u003cstrong\u003eMarch 28, 2025\u003c\/strong\u003e); Preparing \u003cstrong\u003ePhase 2\u003c\/strong\u003e study\u003c\/td\u003e\n\u003ctd\u003eGlobal Market: \u003cstrong\u003e\u0026gt;$20 billion\u003c\/strong\u003e (2029 est.)\u003c\/td\u003e\n\u003ctd\u003eEntolimod™\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdvanced Cancers\u003c\/td\u003e\n\u003ctd\u003eIND received for anti-tumor agent\/treatment-related conditions\u003c\/td\u003e\n\u003ctd\u003ePart of the \u003cstrong\u003e$140 million\u003c\/strong\u003e prior investment\u003c\/td\u003e\n\u003ctd\u003eEntolimod™\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLymphocyte Exhaustion\u003c\/td\u003e\n\u003ctd\u003eOption to License\u003c\/td\u003e\n\u003ctd\u003eCovered by two transferred INDs\u003c\/td\u003e\n\u003ctd\u003eEntolimod™\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImmunosenescence\u003c\/td\u003e\n\u003ctd\u003eOption to License\u003c\/td\u003e\n\u003ctd\u003ePotential indication expansion\u003c\/td\u003e\n\u003ctd\u003eEntalasta™\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003ePipeline Expansion Options:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe license agreement includes an exclusive option to license \u003cstrong\u003efive additional indications\u003c\/strong\u003e initially, which was later specified as three additional indications plus the derivative Entalasta™.\u003c\/li\u003e\n\u003cli\u003eThe three specific additional options are: \u003cstrong\u003eLymphocyte exhaustion\u003c\/strong\u003e, \u003cstrong\u003eImmunosenescence\u003c\/strong\u003e, and \u003cstrong\u003echronic radiation syndrome\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe derivative molecule is named \u003cstrong\u003eEntalasta™\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eTivic Health Systems, Inc. (TIVC) - VRIO Analysis: 3. Optimized Non-Invasive Vagus Nerve Stimulation (ncVNS) Data\n\u003c\/h2\u003e\n\u003cp\u003eProprietary trial findings uncovered key parameters that dramatically enhance autonomic effects for their prescription device pipeline.\u003c\/p\u003e\n\n\u003ch\u003eValue\u003c\/h\u003e\n\u003cp\u003e\u003cstrong\u003eMedium\/High\u003c\/strong\u003e; proprietary trial findings uncovered key parameters that dramatically enhance autonomic effects for their prescription device pipeline.\u003c\/p\u003e\n\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003cp\u003e\u003cstrong\u003eMedium\u003c\/strong\u003e; other firms use ncVNS, but Tivic’s specific, validated optimization parameters are newer to the market. The Optimization Study for the patent-pending ncVNS device has completed all study visits.\u003c\/p\u003e\n\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003cp\u003e\u003cstrong\u003eDifficult\u003c\/strong\u003e; this relies on proprietary clinical trial results and associated new patent filings. The company has 'created new intellectual property. This includes IP captured in patent filings that cover potential breakthroughs in personalizing and optimizing the clinical effects of vagus nerve stimulation.'\u003c\/p\u003e\n\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003cp\u003e\u003cstrong\u003eMedium\u003c\/strong\u003e; the company has completed the optimization study but is now focusing on licensing or commercializing this program.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe company announced it is 'planning to exit the ClearUP business by the end of this year' to maximize focus on the expanded clinical pipeline.\u003c\/li\u003e\n\u003cli\u003eThe company is advancing commercialization of its therapies, including briefings with the White House and FDA regarding potential military and defense applications for its bioelectronic product candidates.\u003c\/li\u003e\n\u003cli\u003eThe company is focusing resources on research and development programs, with Q1 2025 advertising expenses decreasing by 92% year-over-year.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003cp\u003e\u003cstrong\u003eTemporary\u003c\/strong\u003e; the advantage lasts until competitors can replicate the performance through their own R\u0026amp;D or licensing.\u003c\/p\u003e\n\n\u003cp\u003eKey quantitative results from the collaborative clinical optimization study with The Feinstein Institutes include:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eParameter Optimized\u003c\/td\u003e\n\u003ctd\u003eKey Metric\u003c\/td\u003e\n\u003ctd\u003eQuantitative Result\u003c\/td\u003e\n\u003ctd\u003eComparison\/Context\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eStimulation Frequency Personalization\u003c\/td\u003e\n\u003ctd\u003eIncrease in Heart Rate Variability (HRV)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e46%\u003c\/strong\u003e increase\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e8.9x\u003c\/strong\u003e more effective than applying the same frequency to all subjects\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStimulation Duration\u003c\/td\u003e\n\u003ctd\u003eEfficacy\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e4 minutes\u003c\/strong\u003e of stimulation sufficient\u003c\/td\u003e\n\u003ctd\u003eMore effective than twenty minutes of stimulation\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eElectrode Placement\/Configuration\u003c\/td\u003e\n\u003ctd\u003eHRV Modulation\u003c\/td\u003e\n\u003ctd\u003eVaried significantly\u003c\/td\u003e\n\u003ctd\u003eSome placements increased HRV and others markedly reduced it\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003ePrevious pilot study data demonstrated a 97% increase in the root mean square of successive differences (RMSSD) measure of heart rate variability. In 60% of participants in that prior study, raw HRV nearly doubled following ncVNS stimulation.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eTivic Health Systems, Inc. (TIVC) - VRIO Analysis: 4. Expanded Intellectual Property (IP) Portfolio\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e High; new filings protect both the biologics (TLR5 agonists for cancer) and the bioelectronic device specifications, creating licensing leverage.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Medium; many companies have IP, but Tivic’s recent, targeted filings across both platforms are timely and strategic.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Difficult; the legal process of obtaining patents creates a significant barrier to entry for competitors.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; management is actively expanding and protecting IP to create partnership opportunities.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained; legal protection is a durable barrier when actively maintained.\u003c\/p\u003e\n\u003cp\u003eThe expansion of the IP portfolio is evidenced by recent filings covering both the biopharma and bioelectronic platforms, aiming to secure proprietary advantages in novel therapeutic applications and device optimization.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eIP Metric\u003c\/th\u003e\n\u003cth\u003eData Point\u003c\/th\u003e\n\u003cth\u003eContext\/Date Reference\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Global Patents\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e23\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of September 2022\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGranted Patents (Global)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e5\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of September 2022\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eActive Patents (Global)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e19\u003c\/strong\u003e (over \u003cstrong\u003e82%\u003c\/strong\u003e)\u003c\/td\u003e\n\u003ctd\u003eAs of September 2022\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRecent USPTO Filings\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eNovember 2025 filing for TLR5\/Bioelectronic\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUSPTO Grant Rate\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e100%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFor 5 granted applications out of 9 filed at USPTO (excluding Design\/PCT)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eSpecific recent IP expansion activities include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eFiling of a patent application titled “Immunomodulatory Pathway Modifying Agents and Uses of Same for Cancer Therapy” relating to TLR5 agonists (Entolimod and Entolasta) as adjunctive therapy for advanced-stage cancer.\u003c\/li\u003e\n\u003cli\u003eFiling of a patent application titled “Vagus Nerve Electrical Stimulation System” covering device parameters for optimal impact on autonomic system activity via non-invasive vagus nerve stimulation (ncVNS).\u003c\/li\u003e\n\u003cli\u003eThe lead drug candidate, Entolimod™, for Acute Radiation Syndrome (ARS) targets a market estimated at \u003cstrong\u003eUSD 5.2 billion\u003c\/strong\u003e in 2024.\u003c\/li\u003e\n\u003cli\u003eThe acquisition of the Entolimod license involved an initial payment of \u003cstrong\u003e$300,000 cash\u003c\/strong\u003e and \u003cstrong\u003e$1,200,000 in equity consideration\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eTivic Health Systems, Inc. (TIVC) - VRIO Analysis: 5. Government\/Defense Engagement for ARS Countermeasure\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue: High\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDirect engagement with the White House and FDA suggests pathways for large, non-dilutive contracts for the national stockpile. The U.S. Government, through agencies including BARDA, NASA, Defense Threats Reduction Agency, Department of the Army, and the Department of Defense, has previously provided significant funding to the development of Tivic's TLR5 program, including the lead product candidate Entolimod™.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity: High\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSecuring this level of interest for a specific medical countermeasure is rare for a company of this size. The company was valued at $2.17 million as of April 22, 2025.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability: Difficult\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThis is based on established relationships and successful navigation of defense procurement channels. Key government entities engaged include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe \u003cstrong\u003eWhite House\u003c\/strong\u003e senior leadership.\u003c\/li\u003e\n\u003cli\u003eThe \u003cstrong\u003eFDA\u003c\/strong\u003e senior leadership.\u003c\/li\u003e\n\u003cli\u003eThe \u003cstrong\u003eBiomedical Advanced Research and Development Authority (BARDA)\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe \u003cstrong\u003eArmed Forces Radiobiology Research Institute (AFRRI)\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe \u003cstrong\u003eMedical CBRN Defense Consortium (MCDC)\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization: High\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe company actively participated in the 2025 Military Health System Research Symposium (MHSRS) to advance this. The symposium was held August 4-7, 2025, in Kissimmee, Florida. Tivic's President of Biopharma and Chief Operating Officer, Michael Handley, met with key members of BARDA, AFRRI, and MCDC to discuss potential deployment pathways for Entolimod as a military countermeasure.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage: Sustained\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThese relationships are hard-won and difficult for new entrants to replicate quickly. The impact of these discussions is reflected in market reaction and financial context:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue\/Detail\u003c\/td\u003e\n\u003ctd\u003eContext\/Date\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eStock Price Increase Post-Briefing\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e232.6%\u003c\/strong\u003e to \u003cstrong\u003e$11.82\u003c\/strong\u003e premarket\u003c\/td\u003e\n\u003ctd\u003eFollowing White House\/FDA meetings in April 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStock Price Surge Post-MHSRS\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e55%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFollowing announcement of August 2025 MHSRS progress\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrior Financing Raised (Tranches 2, 3, 4)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$3.8 million\u003c\/strong\u003e in net proceeds\u003c\/td\u003e\n\u003ctd\u003eDuring Q3 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash and Cash Equivalents\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$3.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAt September 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ3 2025 Net Loss\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$2.6 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFor the third quarter ended September 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ3 2025 Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$146,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFor the third quarter ended September 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003eTivic Health Systems, Inc. (TIVC) - VRIO Analysis: 6. Debt-Free Capital Structure with Committed Funding\n\u003c\/h2\u003e\n\u003cp\u003e\n\u003ch\u003e\u003ch\u003eValue: High\u003c\/h\u003e\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nHaving no debt on the balance sheet provides significant financial flexibility and avoids interest expense burden.\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eTotal Debt: \u003cstrong\u003e$0.0\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eDebt-to-Equity Ratio: \u003cstrong\u003e0%\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eTotal Liabilities: \u003cstrong\u003e$638.0K\u003c\/strong\u003e as of the latest quarter\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\n\u003ch\u003e\u003ch\u003eRarity: Medium\u003c\/h\u003e\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nMany clinical-stage biotechs carry debt; Tivic relies on equity financing.\n\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eTIVC Value\u003c\/td\u003e\n\u003ctd\u003eContext\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Debt\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$0.0\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eNo debt on balance sheet\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDebt-to-Equity Ratio\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e0%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eIndicates no debt financing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\n\u003ch\u003e\u003ch\u003eImitability: Difficult\u003c\/h\u003e\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nAccess to the committed \u003cstrong\u003e$8.4 million\u003c\/strong\u003e preferred equity purchase agreement tranches is based on prior agreements.\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003ePreferred Purchase Agreement Total Contemplated Financing: Up to \u003cstrong\u003e$8.4 million\u003c\/strong\u003e across six tranches\u003c\/li\u003e\n\u003cli\u003eInitial and Second Tranche Closing Amounts: Each for \u003cstrong\u003e$700,000\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eFinancing Raised from First and Second Tranche: \u003cstrong\u003e$1.4 million\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eRemaining Available Commitment (as of June 30, 2025): Approximately \u003cstrong\u003e$7.0 million\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eAdditional Financing Facility: \u003cstrong\u003e$25 million\u003c\/strong\u003e equity line of credit\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\n\u003ch\u003e\u003ch\u003eOrganization: High\u003c\/h\u003e\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nManagement clearly states that current and committed funding is sufficient for the next key milestone.\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eStated Sufficiency: Current and committed funding is sufficient to make meaningful progress toward manufacturing validation for Entolimod\u003c\/li\u003e\n\u003cli\u003eCash and Cash Equivalents (June 30, 2025): \u003cstrong\u003e$1.2 million\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\n\u003ch\u003e\u003ch\u003eCompetitive Advantage: Sustained\u003c\/h\u003e\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nThe lack of debt is a structural advantage in volatile funding markets.\n\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eStructural Feature\u003c\/td\u003e\n\u003ctd\u003eFinancial Implication\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eZero Debt\u003c\/td\u003e\n\u003ctd\u003eAvoidance of interest expense burden\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCommitted Equity Funding\u003c\/td\u003e\n\u003ctd\u003eAccess to up to \u003cstrong\u003e$8.4 million\u003c\/strong\u003e to fund key milestones\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003eTivic Health Systems, Inc. (TIVC) - VRIO Analysis: 7. Successful cGMP Manufacturing Cell Line Verification\n\u003c\/h2\u003e\n\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003eHigh\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003eMedium\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003eMedium\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003eHigh\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003eTemporary\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eVRIO Component\u003c\/td\u003e\n\u003ctd\u003eAssessment\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003eMedium\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImitability\u003c\/td\u003e\n\u003ctd\u003eMedium\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eStatistical and Financial Numbers Related to Milestone Achievement and Context:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCell line verification completed in the third quarter of 2025, announced on September \u003cstrong\u003e10\u003c\/strong\u003e, 2025.\u003c\/li\u003e\n\u003cli\u003ePartner for production: \u003cstrong\u003eScorpius Biomanufacturing, Inc.\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eNet loss for Q3 2025: \u003cstrong\u003e$2.6 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eCash and cash equivalents as of September 30, 2025: \u003cstrong\u003e$3.5 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eCommitted investment available as of September 30, 2025: Approximately \u003cstrong\u003e$3.5 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eNet proceeds from financing closed in Q3 2025: \u003cstrong\u003e$3.8 million\u003c\/strong\u003e from an \u003cstrong\u003e$8.4 million\u003c\/strong\u003e financing agreement.\u003c\/li\u003e\n\u003cli\u003eOperating expenses for Q3 2025: \u003cstrong\u003e$2.3 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eRevenue for Q3 2025: \u003cstrong\u003e$146,000\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eTivic Health Systems, Inc. (TIVC) - VRIO Analysis: 8. Strategic Focus on Biopharma Pipeline\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue: High\u003c\/strong\u003e; by exiting the consumer business, all capital and management attention are now directed toward high-value prescription therapeutics.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity: Medium\u003c\/strong\u003e; the decisive exit from a revenue-generating product line to focus on R\u0026amp;D is a bold, but increasingly common, strategic move in the sector.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability: Easy\u003c\/strong\u003e; competitors can pivot strategy, but they lack Tivic’s specific pipeline assets.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization: High\u003c\/strong\u003e; the company completed the wind down and launched a new corporate website emphasizing the transformed mission.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage: Temporary\u003c\/strong\u003e; the advantage is the speed of the pivot, which is not inherently sustainable long-term.\u003c\/p\u003e\n\n\u003cp\u003eThe strategic shift is quantified by the decline in consumer revenue and concurrent capital raising for biopharma development:\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue (Q1 2025)\u003c\/td\u003e\n\u003ctd\u003eValue (Q3 2025)\u003c\/td\u003e\n\u003ctd\u003eContext\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eConsumer Revenue (Net)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$70,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$146,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ1 2025 revenue down \u003cstrong\u003e81%\u003c\/strong\u003e from $334,000 (Q1 2024) due to advertising reduction.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClearUP Advertising Spend Change\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e-92%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003eReduction in Q1 2025 to reallocate capital.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInventory\/Equipment Write-off (Exit Cost)\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$347,000\u003c\/strong\u003e Total\u003c\/td\u003e\n\u003ctd\u003eQ3 2025 included $230,000 COGS and $117,000 other expenses for wind down.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancing Raised (Net Proceeds)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$3.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ1 2025 ATM proceeds; Q3 2025 proceeds from $8.4 million financing tranches.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash \u0026amp; Equivalents\u003c\/td\u003e\n\u003ctd\u003e$1.2 million (Q2 End)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$3.5 million\u003c\/strong\u003e (Q3 End)\u003c\/td\u003e\n\u003ctd\u003eUp from $2.0 million at December 31, 2024.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eKey Biopharma Pipeline Milestones Supporting Value:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eEntolimod granted \u003cstrong\u003eFast Track\u003c\/strong\u003e and \u003cstrong\u003eOrphan Drug\u003c\/strong\u003e status by the FDA for Acute Radiation Syndrome (ARS).\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eCompleted cell line verification, a key step for Current Good Manufacturing Practices (cGMP) prior to Biologics License Application (BLA) filing.\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eCompleted all study visits in the Optimization Study for the non-invasive cervical vagus nerve stimulation (ncVNS) device.\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eSuccessfully completed the transfer of two Investigational New Drug (IND) applications from Statera Biopharma for neutropenia and lymphocyte exhaustion.\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eThe company has \u003cstrong\u003eno debt\u003c\/strong\u003e on its balance sheet as of June 30, 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eTivic Health Systems, Inc. (TIVC) - VRIO Analysis: 9. Dual Platform Foundation (Biologics and Bioelectronics)\n\u003c\/h2\u003e\n\u003cp\u003eThe dual platform strategy integrates established bioelectronic medicine with an emerging biopharmaceutical pipeline, representing a strategic pivot for the organization.\u003c\/p\u003e\n\u003ch\u003eValue\u003c\/h\u003e\n\u003cp\u003eMedium; the dual approach targets immune system health through two distinct modalities, offering potential for combination therapies or licensing across different markets. The bioelectronic platform is the basis for the FDA-approved ClearUP Sinus Pain Relief device.\u003c\/p\u003e\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003cp\u003eMedium; few companies maintain active development in both advanced biologics and medical devices simultaneously. The company is advancing its TLR5 agonist program, Entolimod™, for Acute Radiation Syndrome (ARS) alongside its bioelectronic work.\u003c\/p\u003e\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003cp\u003eDifficult; building expertise and regulatory pathways for two distinct technology classes is resource-intensive. The company is preparing for the FDA biologics license application process for Entolimod™.\u003c\/p\u003e\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003cp\u003eMedium; while the focus is on biologics, the bioelectronic program remains a protected, valuable asset for future licensing, though the company plans to exit the ClearUP business by the end of the year.\u003c\/p\u003e\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003cp\u003eTemporary to Sustained; its value depends on successfully advancing both platforms or securing a major licensing deal for one.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eVRIO Attribute\u003c\/td\u003e\n\u003ctd\u003eAssessment\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eMedium\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003eMedium\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImitability\u003c\/td\u003e\n\u003ctd\u003eDifficult\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003eMedium\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompetitive Advantage\u003c\/td\u003e\n\u003ctd\u003eTemporary to Sustained\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eSupporting financial and platform data:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eRevenue (net of returns) for the three months ended June 30, 2025, totaled \u003cstrong\u003e$86,000\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eCash and cash equivalents totaled \u003cstrong\u003e$1.2 million\u003c\/strong\u003e at June 30, 2025.\u003c\/li\u003e\n\u003cli\u003eThe company has \u003cstrong\u003eno debt\u003c\/strong\u003e on its balance sheet as of June 30, 2025.\u003c\/li\u003e\n\u003cli\u003eOperating expenses for the three months ended June 30, 2025, were \u003cstrong\u003e$2.0 million\u003c\/strong\u003e, resulting in a net loss of \u003cstrong\u003e$1.9 million\u003c\/strong\u003e for the period.\u003c\/li\u003e\n\u003cli\u003eThe non-invasive cervical vagus nerve stimulation (ncVNS) device Optimization Study completed all study visits.\u003c\/li\u003e\n\u003cli\u003eEntolimod™ has FDA \u003cstrong\u003eFast Track\u003c\/strong\u003e and \u003cstrong\u003eOrphan Drug\u003c\/strong\u003e designations.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFinance: The preferred equity purchase agreement provides for up to \u003cstrong\u003e$8.4 million\u003c\/strong\u003e in total financing, with approximately \u003cstrong\u003e$7.0 million\u003c\/strong\u003e remaining available as a committed investment subsequent to June 30, 2025.\u003c\/p\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516265160853,"sku":"tivc-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/tivc-vrio-analysis.png?v=1740224031","url":"https:\/\/dcf-model.com\/es\/products\/tivc-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}